Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

azole resistance

  • Open Access
    <em>cyp51A</em> Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the <span class="named-content genus-species" id="named-content-1">Aspergillus viridinutans</span> Species Complex
    Mechanisms of Resistance
    cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex

    The past decade has seen an increase in aspergillosis in humans and animals due to Aspergillus viridinutans species complex members. Azole resistance is common to these infections, carrying a poor prognosis. cyp51A gene mutations are the main cause of acquired azole resistance in Aspergillus...

    Jessica J. Talbot, Jens C. Frisvad, Jacques F. Meis, Ferry Hagen, Paul E. Verweij, David E. Hibbs, Felcia Lai, Paul W. Groundwater, Robert A. Samson, Sarah E. Kidd, Vanessa R. Barrs, Jos Houbraken
  • Open Access
    Extended-Interval Dosing of Rezafungin against Azole-Resistant <span class="named-content genus-species" id="named-content-1">Aspergillus fumigatus</span>
    Experimental Therapeutics
    Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus

    We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus. Survival was significantly improved in mice treated with each dose of rezafungin and supratherapeutic posaconazole (20 mg/...

    Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Brian L. Wickes, Gabriel Catano, Thomas F. Patterson
  • New Insights into the Cyp51 Contribution to Azole Resistance in <em>Aspergillus</em> Section <em>Nigri</em>
    Mechanisms of Resistance
    New Insights into the Cyp51 Contribution to Azole Resistance in Aspergillus Section Nigri

    Invasive aspergillosis (IA) is a severe condition mainly caused by Aspergillus fumigatus, although other species of the genus, such as section Nigri members, can also be involved. Voriconazole (VRC) is the recommended treatment for IA; however, the prevalence of azole-resistant Aspergillus isolates has alarmingly increased in recent years, and the...

    Alba Pérez-Cantero, Loida López-Fernández, Josep Guarro, Javier Capilla
  • <em>In Vitro</em> Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of <em>Candida albicans</em>
    Experimental Therapeutics
    In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans

    The fungal Cyp51-specific inhibitors VT-1161 and VT-1598 have emerged as promising new therapies to combat fungal infections, including Candida spp. To evaluate their in vitro activities compared to other azoles, MICs were determined by Clinical and Laboratory Standards Institute (CLSI) method for VT-1161, VT-1598, fluconazole, voriconazole, itraconazole, and posaconazole against 68 ...

    Andrew T. Nishimoto, Nathan P. Wiederhold, Stephanie A. Flowers, Qing Zhang, Steven L. Kelly, Joachim Morschhäuser, Christopher M. Yates, William J. Hoekstra, Robert J. Schotzinger, Edward P. Garvey, P. David Rogers
  • <em>In Vitro</em> and <em>In Vivo</em> Exposure-Effect Relationship of Liposomal Amphotericin B against <span class="named-content genus-species" id="named-content-1">Aspergillus fumigatus</span>
    Experimental Therapeutics
    In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus

    In vitro pharmacokinetic/pharmacodynamic data of liposomal amphotericin B (L-AMB) were compared with animal data from neutropenic and nonneutropenic models of azole-susceptible and azole-resistant invasive aspergillosis. L-AMB was equally effective.

    Maria Siopi, Johan W. Mouton, Spyros Pournaras, Joseph Meletiadis
  • Contributions of <em>yap1</em> Mutation and Subsequent <em>atrF</em> Upregulation to Voriconazole Resistance in <span class="named-content genus-species" id="named-content-1">Aspergillus flavus</span>
    Mechanisms of Resistance
    Contributions of yap1 Mutation and Subsequent atrF Upregulation to Voriconazole Resistance in Aspergillus flavus

    Aspergillus flavus is the second most significant pathogenic cause of invasive aspergillosis; however, its emergence risks and mechanisms of voriconazole (VRC) resistance have not yet been elucidated in detail. Here, we demonstrate that repeated exposure of A. flavus to subinhibitory concentrations...

    Yuuta Ukai, Miho Kuroiwa, Naoko Kurihara, Hiroki Naruse, Tomoyuki Homma, Hideki Maki, Akira Naito
  • Susceptibility
    Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study)

    Antifungal resistance is increasing by the emergence of intrinsically resistant species and by the development of secondary resistance in susceptible species. A previous study performed in Spain revealed levels of azole resistance in molds of between 10 and 12.7%, but secondary resistance in Aspergillus fumigatus was not detected.

    Ana Alastruey-Izquierdo, Laura Alcazar-Fuoli, Olga Rivero-Menéndez, Josefina Ayats, Carmen Castro, Julio García-Rodríguez, Lidia Goterris-Bonet, Elisa Ibáñez-Martínez, María José Linares-Sicilia, M. Teresa Martin-Gomez, Estrella Martín-Mazuelos, Teresa Pelaez, Javier Peman, Antonio Rezusta, Susana Rojo, Rocio Tejero, Diego Vicente Anza, Jesús Viñuelas, Maria Soledad Zapico, Manuel Cuenca-Estrella
    and on behalf of the FILPOP2 Project from GEMICOMED (SEIMC) and REIPI
  • Mechanisms of Resistance
    Identification of 14-α-Lanosterol Demethylase (CYP51) in Scedosporium Species

    Scedosporium spp. cause infections (scedosporiosis) in both immunocompetent and immunocompromised individuals and may persistently colonize the respiratory tract in patients with cystic fibrosis (CF).

    Anne Bernhardt, Wieland Meyer, Volker Rickerts, Toni Aebischer, Kathrin Tintelnot
  • Mechanisms of Resistance
    Insight into the Significance of Aspergillus fumigatus cyp51A Polymorphisms
    Rocio Garcia-Rubio, Laura Alcazar-Fuoli, Maria Candida Monteiro, Sara Monzon, Isabel Cuesta, Teresa Pelaez, Emilia Mellado
  • Mechanisms of Resistance
    Detection of TR34/L98H CYP51A Mutation through Passive Surveillance for Azole-Resistant Aspergillus fumigatus in the United States from 2015 to 2017
    Elizabeth L. Berkow, Natalie S. Nunnally, Alex Bandea, Randall Kuykendall, Karlyn Beer, Shawn R. Lockhart

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596